Catalyst Dossier · compiled by CeliA 🧫

Emergent BioSolutions Inc. (EBS)

Pharmaceutical Preparations · market cap $413M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-05

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-05Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Ciprofloxacin 500Mg Tablet	Phase 2	Anthrax
Dose of 5.0 x 10^9 CFU (Cohort 1)	Phase 2	Typhoid
Ciprofloxacin	Phase 2	Anthrax
FLU-IGIV	Phase 2	Influenza A H3N2
AV7909	Phase 3	Anthrax
ACAM2000	Phase 3	Smallpox Vaccine Adverse Reaction
BioThrax	Phase 3	Anthrax
Vaccinia virus: ACAM2000 smallpox vaccine	Phase 2	Smallpox
ACAM2000 Smallpox Vaccine	Phase 2	Smallpox
AIGIV 3.5 mg/kg	Phase 2	Anthrax
HuMax-CD4	Phase 3	T Cell Lymphoma

Price & technical context

3-month

-0.2%

6-month

-32.2%

12-month

+29.8%

52-wk range

$5.63–$13.90

vs 50-day MA

-1.0%

vs 200-day MA

-14.8%

Realized vol

79.5%

Max drawdown

-71.2%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for EBS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 11 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.